Resistance to second-generation integrase inhibitors in people with HIV following treatment failure on dolutegravir- or bictegravir-based ART in Taiwan
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkaf488 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Guan-Jhou Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, HIV Infections, HIV Integrase Inhibitors, HIV-1. Die Arbeit nennt 23 Literaturangaben. Gefördert von: Centers for Diseases Control, Taiwan.
Abstract (Originalsprache)
Background
Resistance-associated mutations (RAMs) to second-generation integrase strand-transfer inhibitors (INSTIs) have been increasingly observed among people with HIV (PWH) who experienced virological failure on dolutegravir-based ART. However, data on dolutegravir resistance in the Asia-Pacific region remain limited, and data on RAMs during virological failure while receiving bictegravir-based ART are even more scarce.
Methods
In this multicentre, retrospective study in Taiwan, PWH with treatment failure on second-generation INSTI-based ART and successful amplification of the integrase gene were included. Data collected included HIV-1 subtypes, plasma viral loads (PVLs), CD4 counts and clinical characteristics. RAMs were identified using the 2025 IAS-USA mutation list and interpreted using the Stanford HIVdb algorithm.
Results
From 2016 to 2022, 73 and 127 PWH experienced treatment failure on bictegravir- and dolutegravir-based ART, respectively, and had successful genotypic resistance testing. Median PVL at failure was 4.7 log10 copies/mL, and median CD4 count was 225 cells/mm3, with no significant between-group differences. RAMs to second-generation INSTIs were detected in 5.5% (4/73) of bictegravir- and 4.8% (6/127) of dolutegravir-treated individuals (P = 0.33). Common RAMs included Q148H/K/R (3.5%), G140A/C/R/S (3.0%) and R263K (1.5%), with comparable distributions between the two groups. Among eight PWH retained in care, four achieved viral suppression after switching to salvage ART, and four with continuation of INSTI-based ART.
Conclusions
Although RAMs to second-generation INSTIs may be detected during treatment failure, the overall prevalence remains low for both dolutegravir- and bictegravir-based ART. Viral resuppression can be achieved through salvage therapy or continued use of second-generation INSTI-based regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
- Infection Control Room, Min-Sheng General Hospital, Taoyuan, Taiwan.
- Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
- Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan.
- Department of Tropical Medicine and Parasitology, National Taiwan University College of Medicine, Taipei, Taiwan.
ORCID-Profile: Chien-Ching Hung
Förderung
- Centers for Diseases Control, Taiwan
Zitieren
APA
Chen, G. J., Lee, N. Y., Tsai, M. S., Huang, S. H., Huang, M. H., Lin, C. Y., Liou, B. H., Hung, T. C., Lin, S. P., Su, L. S., Chang, S. Y., & Hung, C. C. (2026). Resistance to second-generation integrase inhibitors in people with HIV following treatment failure on dolutegravir- or bictegravir-based ART in Taiwan. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf488
Vancouver
Chen GJ, Lee NY, Tsai MS, Huang SH, Huang MH, Lin CY, et al. Resistance to second-generation integrase inhibitors in people with HIV following treatment failure on dolutegravir- or bictegravir-based ART in Taiwan. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf488
BibTeX
@article{Chen2026,
author = {Chen, Guan-Jhou and Lee, Nan-Yao and Tsai, Mao-Sung and Huang, Sung-Hsi and Huang, Miao-Hui and Lin, Chi-Ying and Liou, Bo-Huang and Hung, Tung-Che and Lin, Shih-Ping and Su, Li-Shin and Chang, Sui-Yuan and Hung, Chien-Ching},
title = {Resistance to second-generation integrase inhibitors in people with HIV following treatment failure on dolutegravir- or bictegravir-based ART in Taiwan},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkaf488}
}
EUVIMED